Home > Healthcare > Medical Devices > Rehabilitation and Assistive Devices > Neurorehabilitation Devices Market

Neurorehabilitation Devices Market Share

Report ID: GMI7702
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Neurorehabilitation Devices Market Share

The neurorehabilitation devices industry is consolidated, with key players including Bioventus LLC, Hocoma (DIH Medical), Bionik Laboratories Corp., Ekso Bionics Holdings, Inc, and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial position in the market. For instance, in March 2021, Bioventus Inc., a globally recognized leader in active healing solutions, acquired Bioness, Inc., a prominent global player in neuromodulation and rehabilitation medical devices. This strategic acquisition included Bioness's complete product portfolio, encompassing cutting-edge peripheral nerve stimulation ("PNS") therapy and high-quality rehabilitation solutions, along with its active research and development initiatives. This move substantially broadened Bioventus's array of products, leading to increased revenue streams for the company.

Neurorehabilitation Devices Market Companies

Some of the eminent market participants operating in the neurorehabilitation devices industry include:

Bioventus LLC
Ectron Ltd.
Hocoma (DIH Medical)
BIOMETRICS LTD.
Bionik Laboratories Corp.
BioXtreme Ltd.
Ekso bionics holdings, Inc.
Kinestica
Saebo, Inc.
Abbott Laboratories
Emotiv Inc.
BrainCo, Inc
Permobil AB
Medtronic Plc

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for neurorehabilitation devices was valued at USD 1.9 billion in 2023 and is estimated to reach USD 5.8 billion by 2032 as they are designed to aid in the rehabilitation and recovery of individuals with neurological disorders or injuries.

The neurorobotics segment of neurorehabilitation devices industry garnered USD 604 million in 2023 and will grow significantly through 2032 as these devices enable intensive and repetitive training, promoting neuroplasticity and functional recovery.

The U.S. neurorehabilitation devices market accounted for USD 693 million in 2023 and is predicted to witness substantial growth through 2032 attributed to the country's advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of neurological disorders.

Bioventus LLC, Ectron Ltd., Hocoma (DIH Medical), BIOMETRICS LTD., Bionik Laboratories Corp., BioXtreme Ltd., Ekso bionics holdings, Inc., Kinestica, Saebo, Inc., Abbott Laboratories, Emotiv Inc., BrainCo, Inc, Permobil AB, and Medtronic Plc.